Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05182892
Other study ID # 2021-01787
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 13, 2021
Est. completion date February 29, 2024

Study information

Verified date January 2023
Source University Hospital Inselspital, Berne
Contact Paul Krack, Prof.
Phone 31 632 21 68
Email paul.krack@insel.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators' objective is to improve L-dopa sensitive PD-related dysarthria and at the same time reduce DBS-induced speech disorders with the help of automated acoustic analysis in patients with STN-DBS-induced dysarthria.


Description:

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective treatment of L-dopa sensitive motor symptoms of Parkinson's disease (PD) but its effects on speech are equivocal. Although some aspects of speech might improve with STN-DBS, stimulation-induced dysarthria represents one of the most common side effects, with a prevalence of up to 90%. Worsening of speech can neutralize the motor benefits of STN-DBS in terms of overall benefit in quality of life. STN-DBS induced dysarthria is not understood in sufficient detail that would allow its prevention or sustained reduction. The human ear is too limited in quantifying subtle changes in speech and to differentiate between parkinsonian and stimulation induced dysarthria. The investigators' objective is to improve L-dopa sensitive PD-related dysarthria and at the same time reduce DBS-induced speech disorders with the help of automated acoustic analysis in patients with STN-DBS-induced dysarthria. In Part 1, the investigators' aim is to identify the most sensitive and specific speech variables for STN-DBS-related improvement of parkinsonian dysarthria and STN-DBS-induced speech-related side-effects, by application of an automated acoustic speech analysis technique. Patients with STN-DSB induced dysarthria will be examined in their medication ON state. Where possible the study will also be performed in the medication OFF state (after an overnight withdrawal of their PD medication). In both states, speech analysis will be performed in the stimulation OFF and ON states, as well as with increasing stimulation amplitudes. In Part 2, the investigators' aim at investigating the anatomical and pathophysiological substrates of STN-DBS induced changes in speech production, by establishing stimulation maps. Stimulation maps highlight effective regions of stimulation and can help clinicians to navigate and program DBS steering the current towards the target region that improves speech (here a priori the sensorimotor STN for improving parkinsonian speech together with other parkinsonian signs), while avoiding current diffusion to regions identified as potentially worsening speech. Part 3 is explorative. The investigators' hypothesize, that selected speech variables in automated speech analysis (as identified in part 1+2) are more sensitive to improvement of STN-DBS induced dysarthria, than ratings of three blinded speech-therapists. Again patients with STN-DBS induced dysarthria will be recruited to this study (willing participants of part 1+2 and patients who did not participate in part 1+2 will be included). The investigators will assess dysarthria by automated speech analysis, expert ratings and subjective ratings, before (at baseline visit) and at two time points (at V1 between 0-6 weeks after baseline and at V2 between 6-12 weeks after V1) after measures are taken to reduce stimulation induced dysarthria. Measures to reduce STN-DBS induced dysarthria will include all DBS settings that are routinely applied in daily clinical practice for dysarthria reduction. DBS-settings will be performed on both DBS-leads and patients will be in the medication ON state.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date February 29, 2024
Est. primary completion date November 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Idiopathic Parkinson-Syndrome according to the Movement Disorders Society Criteria - Treatment with bilateral deep brain stimulation in the subthalamic nucleus (for parts 1, 2 and 3) - Time since DBS-STN operation = 3 month (for parts 1, 2 and 3) - Able to give informed consent as documented by signature - Fluent in Swiss-German or German - STN-DBS-induced dysarthria. In an operational definition, all PD-patients who reported -worsening of speech time-locked to STN-DBS implantation or patients with dysarthria on chronic stimulation improving with reduction of stimulation amplitudes in the context of postoperative routine follow up will be defined as having STN-DBS-induced dysarthria Exclusion Criteria: - Dysarthria caused in addition by a condition other than PD or DBS (e.g. stroke, myasthenia) - Clinical diagnosis of aphasia - Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders and dementia. A Montreal Cognitive Assesment (MoCa) will be performed and patients with = 20 of 30 points will be excluded - Change of parkinsonian medication in the last four weeks prior to inclusion in part 1 and 3 - Change of STN-DBS parameters in the last four weeks prior to inclusion (for parts 1 and 3) - Depression with acute suicidal ideation - Pregnant women

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Change of stimulation amplitudes in dopaminergic OFF drug state
Change of stimulation amplitudes during experiment in dopaminergic OFF drug state.

Locations

Country Name City State
Czechia Czech Technical University Prague Prague
Switzerland University Hospital Inselspital, Berne Bern

Sponsors (2)

Lead Sponsor Collaborator
University Hospital Inselspital, Berne Czech Technical University in Prague

Countries where clinical trial is conducted

Czechia,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1: Identification of the most sensitive and specific speech variables Identification of the most sensitive and specific speech variables of an automated acoustic analysis method, for STN-DBS-related improvement as well as worsening of speech in PD patients, under the two conditions (dopaminergic ON and OFF drug state).
Speech variables will be extracted from the automated acoustic analysis.
At visit 1 (baseline visit)
Primary Part 1: Identification of the most sensitive and specific speech variables Identification of the most sensitive and specific speech variables of an automated acoustic analysis method, for STN-DBS-related improvement as well as worsening of speech in PD patients, under the two conditions (dopaminergic ON and OFF drug state).
Speech variables will be extracted from the automated acoustic analysis.
At visit 2 (=4 weeks after visit 1)
Primary Part 2, Speech analysis: Investigation of spatial overlap of volume of tissue activated (VTA) and the corticobulbar/corticospinal tract Investigation of spatial overlap of tissue activated (VTA) and the corticobulbar/corticospinal tract, in relation to the dysarthria-worsening. 12 months
Primary Part 2, Speech analysis: Investigation of spatial overlap of VTA and the dorsolateral (sensorimotor) STN Investigation of spatial overlap of VTA and the dorsolateral (sensorimotor) STN in relation to improvement of PD-related dysarthria. 12 months
Primary Part 3: Perceptual speech ratings To test if the model 'perceptual speech ratings' explains subjective improvement of STN-DBS induced dysarthria.
Perceptive rating will be performed by three experienced speech therapists, who will rate speech on a visual analogue scale (VAS).
At baseline visit
Primary Part 3: Perceptual speech ratings To test if the model 'perceptual speech ratings' explains subjective improvement of STN-DBS induced dysarthria.
Perceptive rating will be performed by three experienced speech therapists, who will rate speech on a visual analogue scale (VAS).
At visit 1 (0-6 weeks after baseline)
Primary Part 3: Perceptual speech ratings To test if the model 'perceptual speech ratings' explains subjective improvement of STN-DBS induced dysarthria.
Perceptive rating will be performed by three experienced speech therapists, who will rate speech on a visual analogue scale (VAS).
At visit 2 (6-12 weeks after visit 1)
Primary Part 3: Automated speech analysis To test if the model 'automated speech analysis' explains subjective improvement of STN-DBS induced dysarthria.
From the automated speech analysis, only the speech parameters explaining most of the variance in the model from part 2 will be included in the analysis.
At baseline visit
Primary Part 3: Automated speech analysis To test if the model 'automated speech analysis' explains subjective improvement of STN-DBS induced dysarthria.
From the automated speech analysis, only the speech parameters explaining most of the variance in the model from part 2 will be included in the analysis.
At visit 1 (0-6 weeks after baseline)
Primary Part 3: Automated speech analysis To test if the model 'automated speech analysis' explains subjective improvement of STN-DBS induced dysarthria.
From the automated speech analysis, only the speech parameters explaining most of the variance in the model from part 2 will be included in the analysis.
At visit 2 (6-12 weeks after visit 1)
Secondary Part 1: Subjective rating of the quality of speech Subjective rating of the quality of speech on a numeric rating scale by the patient, ranging from 0 = no impairment to 10 = maximum conceivable impairment of speech. Assessment will be performed under the two conditions (dopaminergic ON and OFF drug state). At visit 1 (baseline visit) and visit 2 (=4 weeks)
Secondary Part 1: Assessment parkinsonism contralateral to the tested DBS lead Assessment parkinsonism contralateral to the tested DBS lead using items 3.4 (finger tapping), 3.5 (hand movements), 3.7 (toe tapping) and 3.8 (leg agility) of the Movement Disorders Society-Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS part III) for the limbs contralateral to the tested DBS electrode. Assessment will be performed under the two conditions (dopaminergic ON and OFF drug state). At visit 1 (baseline visit) and visit 2 (=4 weeks)
Secondary Part 1: Clinical assessment of possible side effects Noting possible side effects that may occur during the experiment, such as fascial spasm or contraction of the hand muscles. Assessment will be performed under the two conditions (dopaminergic ON and OFF drug state). At visit 1 (baseline visit) and visit 2 (=4 weeks)
Secondary Part 3: Subjective rating of the quality of speech Subjective rating of the quality of speech on a numeric rating scale by the patient, ranging from 0 = no impairment to 10 = maximum conceivable impairment of speech. At baseline visit, visit 1 (0-6 weeks after baseline) and visit 2 (6-12 weeks after visit 1)
Secondary Part 3: Assessment of motoric symptoms Assessment of Parkinsonism using the full Movement Disorders Society-Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS part III). At baseline visit, visit 1 (0-6 weeks after baseline) and visit 2 (6-12 weeks after visit 1)
Secondary Part 3: Clinical assessment of possible side effects Noting possible side effects that may occur during the experiment, such as fascial spasm or contraction of the hand muscles. At baseline visit, visit 1 (0-6 weeks after baseline) and visit 2 (6-12 weeks after visit 1)
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Recruiting NCT04788693 - Effects of Gait Rehabilitation With Motor Imagery in People With Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A